Navigation Links
Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
Date:2/21/2008

are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would. For example, statements concerning new products, potential regulatory approvals, customer adoption and potential milestone payments are all forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to: (i) the risk that new products, including the PROCLEIX ULTRIO assay, will not be cleared for marketing in the timeframes we expect, if at all, (ii) the risk that we may not earn or receive milestone payments from our collaborators, (iii) the possibility that the market for the sale of our new products, such as our PROCLEIX ULTRIO assay and PROCLEIX TIGRIS system, may not develop as expected, (iv) we may not be able to compete effectively, (v) we may not be able to maintain our current corporate collaborations and enter into new corporate collaborations or customer contracts, and (vi) we are dependent on Novartis and other third parties for the distribution of some of our products. The foregoing describes some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements. For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we file with the SEC, including our most recent annual report on Form 10-K and all subsequent periodic reports. We assume no obligation and expressly disclaim any duty to update any forward-looking sta
'/>"/>
SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
2. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
3. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
4. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
5. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
6. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
8. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
9. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
10. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
11. EpiCept Provides Update on Clinical and Regulatory Progress with Ceplene(TM) and EpiCept(TM) NP-1 Cream
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014  Air Products (NYSE: ... of medical oxygen is vital to any healthcare facility. ... that not only improve the efficiency of its oxygen ... will highlight these systems—including systems for emergency oxygen ... loss—from August 4-5 at the 51 st ...
(Date:7/28/2014)... 28, 2014 Research and Markets  has announced ... 2014-2018" report to their offering. ... that leads to inflammation and pain in the human body,s ... addition, it causes inflammation of the tissues that surround the ... symptoms of RA begin slowly, usually just mild pain around ...
(Date:7/28/2014)... , July 28, 2014  TNI BioTech, Inc. ... company focused on the development, marketing and distribution ... filed definitive proxy materials with the Securities and ... Meeting of Shareholders to be held on Thursday, ... Time. The record date for determining those shareholders ...
Breaking Medicine Technology:Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 2Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 3Global Rheumatoid Arthritis Drugs Market 2014-2018 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3
... The U.S. Food and Drug Administration today announced that monthly ... Letairis tablets (ambrisentan), used to treat high blood pressure in ... hypertension, or PAH). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... the FDA said that the drug poses only a low ...
... 4, 2011 Sigma-Aldrich Corporation (Nasdaq: SIAL ) ... 31st Annual Cowen and Company Healthcare Conference ... Place, Boston, MA, presenting at 10:15 AM (EST). Barclays ... the Loews Miami Hotel, Miami, FL, presenting at 10:15 AM ...
Cached Medicine Technology:FDA Modifies Boxed Warning For Pulmonary Arterial Hypertension Drug Letairis 2FDA Modifies Boxed Warning For Pulmonary Arterial Hypertension Drug Letairis 3
(Date:7/28/2014)... 29, 2014 The “Tissue ... Hybridization, Digital pathology & Workflow, Special Staining), ... Cancer, Non Small Cell Lung Cancer and ... Pharmaceutical companies, Research Laboratories, Contract Research Organizations ... Europe, BRIC, Japan & RoW) - Trends ...
(Date:7/28/2014)... Ariz (PRWEB) July 28, 2014 ... on a new camp property in Cornville, AZ. ... seriously ill children with the opportunity to attend ... campers and families. The organization offers a variety ... 6-15 with chronic and life threatening illnesses including: ...
(Date:7/28/2014)... 28, 2014 An estimated 68,000 women ... metastatic breast and prostate cancers – an aggressive form ... spread to other parts of the body, such as ... Drexel University College of Medicine have developed ... inhibits metastatic progression by blocking tumor cells from “re-seeding.” ...
(Date:7/28/2014)... a surgical procedure to treat severe chronic migraine headaches ... of the time in patients treated at Massachusetts General ... Plastic and Reconstructive Surgery report that more than half ... all of whom had headaches associated with compression of ... later. The team,s paper has received advance online ...
(Date:7/28/2014)... Glutamine is the most abundant single amino ... conditionally essential during times when the body undergoes large ... Immune System Support. , Having a heavy work out ... with additional glutamine may be advantageous. Glutamine supplementation may ... digestion and immune system function. Stress on the body ...
Breaking Medicine News(10 mins):Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 3Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 4Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 5Health News:Camp Soaring Eagle Announces New Camp Site 2Health News:Camp Soaring Eagle Announces New Camp Site 3Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 2Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 3Health News:Non-endoscopic migraine surgery provides significant symptom relief 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3
... the blood is not associated with a reduced risk ... online May 27 in the Journal of the ... high doses of vitamin D may reduce the risk ... the relationship have reported inconsistent results. , In a ...
... finds evidence of slight link between higher concentrations, aggressive ... Men with a high blood concentration of vitamin D ... Cancer Institute researchers report. , Previous laboratory studies had ... prostate cancer risk, but epidemiological studies of that association ...
... Researchers have uncovered a completely unexpected way that the brain ... protective protein to nearby neurons. , Astrocytes are a type ... one of their roles is to chew up damaged nerves ... damaged area. , Roger Chung and colleagues have now ...
... higher in low-expenditure areas than in high-expenditure ones, study ... levels of spending on medical care don,t improve patients, ... who conducted a survey of Medicare beneficiaries. , Per ... United States and differences in health don,t account for ...
... review suggests they may help cancer cells resist chemo, ... new review of existing research suggests that cancer patients ... of antioxidants. , Although multivitamins may be all right ... or E supplements can spell trouble, said review author ...
... Environmentally friendly is not a phrase normally used to ... discovery at Tel Aviv University, the chemical industry is ... Arkadi Vigalok from the School of Chemistry at Tel ... to make certain steps of a complicated chain of ...
Cached Medicine News:Health News:No association found between vitamin D concentration in blood and risk of prostate cancer 2Health News:Vitamin D Status Not Associated With Lower Prostate Risk 2Health News:Spending Doesn't Improve Patients' Perception of Care 2Health News:Cancer Patients Should Steer Clear of Antioxidants 2Health News:Cancer Patients Should Steer Clear of Antioxidants 3Health News:1 small step for a lab science, 1 green leap for mankind 2
... to use: when presented in convenient, ... easy to pick up directly from ... the 96 tips are loaded without ... with a security sticker. Fully autoclavable, ...
This pipette tip facilitates the loading of samples onto polyacrylamide gels for DNA sequencing. The Geloader Tip has a 15 mm capillary with a defined diameter of less than 0.3 mm. The flexibility of...
1200 L, Racked, 96 tips/rack, 10 racks/box Recommended for 1200 L SofTouch electronic pipettes....
Designed to fit the Brinkmann Tranferpette and Treff Multi-Channel 300 L Pipettors, this tip provides extra space for repeat pipetting....
Medicine Products: